/RCKT

Rocket Pharmaceuticals Inc

RCKT

$3.35USD↓-3.74%-0.13 today

MARKET CAP

367.7M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$3 – $4

52W RANGE

$3

$5

AI Summary

Stalk

StalkMedium

RCKT is in a Stage 2 advance after clearing the 3.55 resistance on strong volume. Price is now extended above rising EMAs with extreme overbought readings on RSI and Options Score. While the medium-term trend remains bullish following the Momentum Breakout, timing is unfavorable until a pullback into the 9/21 EMA zone and prior breakout level near 3.55 offers cleaner entry.

↑Anticipated resumption of Danon disease trial after FDA alignment
↑Low-dose cohort showed NYHA class improvements, advancing to Phase 2
↓Negative earnings yield and poor profitability raise operational sustainability concerns

Full analysis →

Buying

7

institutions

Selling

4

institutions

New Positions

0

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕	Action↕	Shares Held↕	Value↓	Change↕	Chg %↕	Weight↕
BI Blackrock, Inc. Q2 2026	BUY	9.92 M	33.94 M	+2.09 M	+21.0%	0.00%
MM Millennium Management LLC Q2 2026	BUY	4.00 M	13.68 M	+882.22 K	+22.6%	0.01%
AC Aqr Capital Management LLC Q2 2026	BUY	3.39 M	11.58 M	+316.23 K	+5.4%	0.00%
JC Jpmorgan Chase & Co Q2 2026	BUY	1.99 M	6.70 M	+1.19 M	+144.3%	0.00%
RT Renaissance Technologies LLC Q2 2026	BUY	792.97 K	2.71 M	+155.80 K	+18.9%	0.00%
PA Point72 Asset Management, L.P. Q2 2026	SELL	670.53 K	2.29 M	+-341.60 K	-36.7%	0.00%
WP Woodline Partners LP Q2 2026	SELL	641.22 K	2.19 M	+-641.22 K	-52.2%	0.01%
AC Adar1 Capital Management, LLC Q2 2026	BUY	435.50 K	1.49 M	+3.00 K	-3.8%	0.07%
CA Citadel Advisors LLC Q2 2026	BUY	136.17 K	465.70 K	+3.97 K	-1.6%	0.00%
BA Balyasny Asset Management L.P. Q2 2026	SELL	94.26 K	322.38 K	+-164.74 K	-65.2%	0.00%
RC Rockefeller Capital Management L.P. Q2 2026	SELL	34.92 K	119.42 K	+-32.91 K	-50.8%	0.00%